https://doi.org/10.5217/ir.2023.00043 • Intest Res 2024;22(2):172-185

Supplementary Table 4. Primary Efficacy Endpoint and Key Clinical Outcomes in LUCENT-1 and LUCENT-2 for the Japanese and Non-Japanese Populations

	Japanese population		Non–Japanese population	
LUCENT-1 (induction)	Placebo	Miri 300 mg	Placebo	Miri 300 mg
Clinical remission	1/35 (2.9)	33/102 (32.4)	38/259 (14.7)	177/766 (23.1)
Clinical response	8/35 (22.9)	73/102 (71.6)	116/259 (44.8)	478/766 (62.4)
Endoscopic improvement	3/35 (8.6)	42/102 (41.2)	59/259 (22.8)	273/766 (35.6)
Histologic-endoscopic improvement	2/35 (5.7)	33/102 (32.4)	39/259 (15.1)	202/766 (26.4)
Symptomatic remission	4/35 (11.4)	56/102 (54.9)	78/259 (30.1)	339/766 (44.3)
LUCENT-2 (maintenance)	Placebo	Miri 200 mg	Placebo	Miri 200 mg
Clinical remission	7/25 (28.0)	23/47 (48.9)	38/154 (24.7)	159/318 (50.0)
CS-free clinical remission	7/25 (28.0)	21/47 (44.7)	32/154 (20.8)	143/318 (45.0)
Maintenance of clinical remission	5/11 (45.5)	13/22 (59.1)	19/54 (35.2)	78/121 (64.5)
Endoscopic improvement	7/25 (28.0)	27/47 (57.4)	45/154 (29.2)	187/318 (58.8)
Histologic-endoscopic improvement plus absence of neutrophils	6/25 (24.0)	23/47 (48.9)	33/154 (21.4)	135/318 (42.5)
Bowel urgency NRS of 0 or 1	6/22 (27.3)	16/40 (40.0)	37/150 (24.7)	128/296 (43.2)

Values are presented as number of responders/total number of patients (%).
Miri, mirikizumab; CS, corticosteroid; NRS, numeric rating scale.